Company Overview and News

 
Hotel Leelaventure gets shareholders nod to sell land in Pune for Rs 130 crore

2018-09-01 moneycontrol
Hotel Leelaventure on Saturday said its shareholders have given their consent to sell the company's land in Pune to Leela Lace Holdings Pvt Ltd for a consideration of Rs 130 crore.
500193 HOTELEELA

 
Promoters forgo salary for second straight year as Hotel Leela#39;s financial mess worsens

2018-08-14 moneycontrol
The chairman and co-chairman of Hotel Leelaventure were forced to forgo their full salaries for the financial year ended March as the company continued to grapple with a huge pile of debt on its books.
500193 HOTELEELA

 
Hotel Leelaventure defaults on payment of quarterly interest to Life Insurance Corporation of India

2018-06-22 moneycontrol
Cash-strapped hospitality chain Hotel Leela Venture has defaulted in payment of quarterly interest of Rs 2.12 crore to Life Insurance Corporation of India (LIC).
500193 HOTELEELA

 
Hotel Leela board to consider 125 cr share issue to JM Financial

2018-06-04 moneycontrol
Hotel Leela Venture today said its board will meet on June 11 to approve a share issue of up to 125 crore shares on preferential basis to JM Financial Asset Reconstruction Company for converting of part of debt into equity.
523405 500193 HOTELEELA JMFINANCIL

 
Hotel Leelaventure defaults on NCD interest to LIC

2018-04-17 thehindubusinessline
Our Bureau Hotel Leelaventure on Tuesday said that it has defaulted on interest and principal payments since 2016, on the ₹90-crore non-convertible debentures issued to Life Insurance Corporation of India.
500193 HOTELEELA 500696 HINDUNILVR

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

10h - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

10h - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

12h - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...